Bitting L, Naidu A, Cordell B, Murphy G M
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
J Biol Chem. 1996 Jul 5;271(27):16084-9. doi: 10.1074/jbc.271.27.16084.
beta-Amyloid protein (betaAP) deposition is a neuropathologic hallmark of Alzheimer's disease (AD). Yet, the source of cerebral betaAP in AD is controversial. We examined the production of betaAP by the BV-2 immortalized microglial cell line using a sensitive enzyme immunoassay. Constitutive production of betaAP was detected in conditioned media from unstimulated BV-2 cells. Further, production of betaAP was induced by treatment of cultures by lipopolysaccharide (LPS) or betaAP-(25-35) and was inhibited by the calpain protease inhibitor MDL 28170. Treatment of BV-2 cells with LPS or betaAP-(25-35) did not affect cell-associated beta-amyloid precursor protein levels. These findings suggest that microglia may be an important source of betaAP in AD, and that microglial production of betaAP may be augmented by proinflammatory stimuli or by betaAP itself.
β-淀粉样蛋白(βAP)沉积是阿尔茨海默病(AD)的神经病理学标志。然而,AD中脑内βAP的来源存在争议。我们使用灵敏的酶免疫测定法检测了BV-2永生化小胶质细胞系中βAP的产生。在未刺激的BV-2细胞的条件培养基中检测到βAP的组成性产生。此外,脂多糖(LPS)或βAP-(25-35)处理培养物可诱导βAP的产生,而钙蛋白酶抑制剂MDL 28170可抑制其产生。用LPS或βAP-(25-35)处理BV-2细胞不影响细胞相关的β-淀粉样前体蛋白水平。这些发现表明,小胶质细胞可能是AD中βAP的重要来源,并且促炎刺激或βAP本身可能会增加小胶质细胞产生βAP的量。